Onderneming Longboard Pharmaceuticals, Inc.
Aandelen
LBPH
US54300N1037
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
20,21 USD | +8,25% | +18,88% | +235,16% |
Vakgebied
Aantal werknemers: 50
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 03-01-20 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 01-01-21 |
Chief Tech/Sci/R&D Officer | - | - | |
Dewey McLin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Randall Kaye
CTO | Chief Tech/Sci/R&D Officer | 62 | 21-03-22 |
Julie Baker
PRN | Corporate Officer/Principal | - | 01-01-23 |
Gus Cardenas
PRN | Corporate Officer/Principal | - | - |
Anne Danks
PRN | Corporate Officer/Principal | - | - |
Marco Peters
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 01-12-20 |
Director/Board Member | 68 | 01-12-20 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 01-02-20 |
Casey Lynch
BRD | Director/Board Member | 50 | 01-02-21 |
Kevin Lind
CEO | Chief Executive Officer | 47 | 03-01-20 |
Corinne Le Goff
BRD | Director/Board Member | 58 | 01-03-21 |
Jane Tiller
BRD | Director/Board Member | 59 | 15-11-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 2 420 755 | 0 | 0 | 92,22 % |
Aandeel B | 1 | 33 607 490 | 33 226 030 ( 98,86 %) | 0 |
Bedrijfsgegevens
Longboard Pharmaceuticals, Inc.
4275 Executive Square Suite 950
92037, La Jolla
+
http://www.longboardpharma.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+235,16% | 726 mln. | |
-0,49% | 103 mld. | |
+3,31% | 96,73 mld. | |
+1,66% | 21,31 mld. | |
-16,16% | 21,21 mld. | |
-6,82% | 18,79 mld. | |
-41,41% | 16,37 mld. | |
-22,87% | 13,68 mld. | |
+6,32% | 13,44 mld. | |
+21,46% | 10,98 mld. |
- Beurs
- Aandelen
- Koers LBPH
- Onderneming Longboard Pharmaceuticals, Inc.